FDA Extends Review of Opzelura for Pediatric Atopic Dermatitis
Incyte’s sNDA for ruxolitinib cream in children ages 2–11 now faces a new action date to allow additional data review.
Tag: opzelura
All
Popular
All
LatestSorry, No Posts Found
All
Latest
Allergan Wins First Approval for Short-Acting Neurotoxin in Canada
The product is the first botulinum toxin type E approved for aesthetic use and is designed to deliver faster onset and shorter-lasting results than traditional neurotoxins.
